Stockscreener 앱 받기
34.87
0.23%
0.08
시간 외 거래:
35.00
0.13
+0.37%
전일 마감가:
$34.79
열려 있는:
$35.41
하루 거래량:
1.89M
Relative Volume:
0.80
시가총액:
$4.05B
수익:
-
순이익/손실:
$-472.34M
주가수익비율:
-8.4107
EPS:
-4.1459
순현금흐름:
$-340.33M
1주 성능:
-4.15%
1개월 성능:
-8.33%
6개월 성능:
+11.05%
1년 성능:
+1.31%
1일 변동 폭
$34.64
$36.12
1주일 범위
$34.39
$38.16
52주 변동 폭
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.87 | 4.04B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness - Moomoo
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29 - TechStock²
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT - TradingView
Viking Therapeutics Inc (VKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Viking Therapeutics Inc (VKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viking Therapeutics Inc (VKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Viking Therapeutics Inc (VKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Inc (VKTX) Institutional Confidence - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620 - TradingKey
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Inc (VKTX) Fundamental & Financial Data - Stocktwits
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics (VKTX.US) will release its earnings report after market close on July 29. - 富途牛牛
Viking Therapeutics Inc (VKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News - Yahoo Finance
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market - Yahoo! Finance Canada
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults - AOL.com
Viking Therapeutics adds Dorothy Gemmell to board of directors By Investing.com - Investing.com South Africa
Viking Therapeutics adds Dorothy Gemmell to board of directors - Investing.com
Press Release: Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors - Moomoo
Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Grows - Sahm
Viking Therapeutics to report Q2 2026 results on July 29 - scanx.trade
Viking Therapeutics to Report Financial Results for Second Quart - GuruFocus
Viking Therapeutics’ Q2 results arrive after markets close - Stock Titan
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 - Sahm
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
(VKTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to C - GuruFocus
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Morningstar
Viking Therapeutics (VKTX) Stock Analysis: Biotechnology’s Hidden Gem with a 154% Potential Upside - DirectorsTalk Interviews
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Investigation into Viking Therapeutics Officers for Fiduciary Breach - Intellectia AI
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 - The Motley Fool
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week - TechStock²
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." - The Motley Fool
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." - The Motley Fool
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial - simplywall.st
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock? - The Globe and Mail
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):